Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633842 | 0.92 | KMT2A (0.43) | SMN1; SMN2KMT2AGAARAB9AL3MBTL1 | |
| SCHEMBL8076154 | 0.80 | GAA (0.39) | SMN1; SMN2KMT2AGAARAB9AL3MBTL1 | |
| SCHEMBL12391710 | 0.79 | LMNA (0.46) | GAAPIK3CDTSHRLMNACA12 | |
| SCHEMBL23645837 | 0.77 | PIK3CD (0.47) | SMN1; SMN2KMT2ARAB9AL3MBTL1PIK3CD | |
| SCHEMBL1978043 | 0.75 | PIK3CD (0.51) | SMN1; SMN2KMT2ARAB9APIK3CDNPC1 | |
| SCHEMBL31482294 | 0.74 | GAA (0.62) | SMN1; SMN2KMT2AGAARAB9AALDH1A1 | |
| Triacetin SCHEMBL28102878 | 0.74 | PIK3CD (0.41) | SMN1; SMN2KMT2AGAAL3MBTL1PIK3CD | |
| SCHEMBL104477 | 0.73 | PIK3CD (0.61) | KMT2ARAB9APIK3CDNPC1TSHR | |
| SCHEMBL14488847 | 0.72 | PIK3CD (0.47) | SMN1; SMN2KMT2APIK3CDALDH1A1TSHR | |
| SCHEMBL28484539 | 0.72 | GAA (0.46) | SMN1; SMN2KMT2AGAARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024330-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230255942-A1 | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | QUOTIENT SCIENCES LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255942-A1 | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | CRHR1, MC2R, CRHR2 | SMN1; SMN2 2707/4885KMT2A 2805/4885GAA 2203/4885 |
| US-20240024330-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRHR2, MC2R | SMN1; SMN2 2348/4885KMT2A 3173/4885GAA 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.